

# Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

https://marketpublishers.com/r/D18A140EE977EN.html

Date: October 2022

Pages: 142

Price: US\$ 2,000.00 (Single User License)

ID: D18A140EE977EN

## **Abstracts**

Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

#### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

#### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.



The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 18, 11, 1, 1, 15, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

#### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diabetic Foot Ulcers



(Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

#### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.



Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## **Contents**

Introduction

Global Markets Direct Report Coverage

Diabetic Foot Ulcers - Overview

Diabetic Foot Ulcers - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Foot Ulcers - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development

Diabetic Foot Ulcers - Drug Profiles

#### 3K3A-APC - DRUG PROFILE

**Product Description** 

Mechanism Of Action

Amesanar - Drug Profile

**Product Description** 

Mechanism Of Action

AP-185 - Drug Profile

**Product Description** 

Mechanism Of Action

APO-2 - Drug Profile

**Product Description** 

Mechanism Of Action

ASCP-02 - Drug Profile

**Product Description** 

Mechanism Of Action

AUP-16 - Drug Profile

**Product Description** 

Mechanism Of Action

AV-001 - Drug Profile



**Product Description** 

Mechanism Of Action

BB-101 - Drug Profile

**Product Description** 

Mechanism Of Action

BFP-001 - Drug Profile

**Product Description** 

Mechanism Of Action

BFP-101 - Drug Profile

**Product Description** 

Mechanism Of Action

Biologic for Diabetic Foot Ulcers - Drug Profile

**Product Description** 

Mechanism Of Action

Cell Therapy for Diabetic Foot Ulcer - Drug Profile

**Product Description** 

Mechanism Of Action

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug

**Profile** 

**Product Description** 

Mechanism Of Action

CHF-6467 - Drug Profile

**Product Description** 

Mechanism Of Action

Corlicyte - Drug Profile

**Product Description** 

Mechanism Of Action

CSA-144 - Drug Profile

**Product Description** 

Mechanism Of Action

CTX-001 - Drug Profile

**Product Description** 

Mechanism Of Action

CVBT-141 - Drug Profile

**Product Description** 

Mechanism Of Action

CVBT-141B - Drug Profile

**Product Description** 



CYP-006TK - Drug Profile

**Product Description** 

Mechanism Of Action

diperoxochloric acid - Drug Profile

**Product Description** 

Mechanism Of Action

donaperminogene seltoplasmid - Drug Profile

**Product Description** 

Mechanism Of Action

Drug for Diabetic Foot Ulcer - Drug Profile

**Product Description** 

Mechanism Of Action

ENERGIF-703 - Drug Profile

**Product Description** 

Mechanism Of Action

Epoetin alfa - Drug Profile

**Product Description** 

Mechanism Of Action

EscharEx - Drug Profile

**Product Description** 

Mechanism Of Action

EscharEx Second Generation - Drug Profile

**Product Description** 

Mechanism Of Action

esmolol hydrochloride - Drug Profile

**Product Description** 

Mechanism Of Action

exeporfinium chloride - Drug Profile

**Product Description** 

Mechanism Of Action

FGF-1 - Drug Profile

**Product Description** 

Mechanism Of Action

Gene Therapy for Diabetic Foot Ulcers and Wound - Drug Profile

**Product Description** 

Mechanism Of Action

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile

**Product Description** 



ISN-001 - Drug Profile

**Product Description** 

Mechanism Of Action

MR-MC-01 - Drug Profile

**Product Description** 

Mechanism Of Action

MSC Exosomal Topical Suspension - Drug Profile

**Product Description** 

Mechanism Of Action

MT-003 - Drug Profile

**Product Description** 

Mechanism Of Action

Mul-1867 - Drug Profile

**Product Description** 

Mechanism Of Action

NORS-2791 - Drug Profile

**Product Description** 

Mechanism Of Action

Nu-3 - Drug Profile

**Product Description** 

Mechanism Of Action

OLX-106 - Drug Profile

**Product Description** 

Mechanism Of Action

PCSPH-08 - Drug Profile

**Product Description** 

Mechanism Of Action

PP-2351 - Drug Profile

**Product Description** 

Mechanism Of Action

RECCE-327 - Drug Profile

**Product Description** 

Mechanism Of Action

Recombinant Human Platelet-Derived Growth Factor Gel - Drug Profile

**Product Description** 

Mechanism Of Action

recombinant plasminogen - Drug Profile

**Product Description** 



rhPDGF-BB - Drug Profile

**Product Description** 

Mechanism Of Action

ropocamptide - Drug Profile

**Product Description** 

Mechanism Of Action

RP-557 - Drug Profile

**Product Description** 

Mechanism Of Action

rusalatide acetate - Drug Profile

**Product Description** 

Mechanism Of Action

SER-190 - Drug Profile

**Product Description** 

Mechanism Of Action

SLIF-06 - Drug Profile

**Product Description** 

Mechanism Of Action

Small Molecule for Diabetic Foot Ulcers - Drug Profile

**Product Description** 

Mechanism Of Action

Small Molecule to Inhibit NOX for Diabetic Foot Ulcers - Drug Profile

**Product Description** 

Mechanism Of Action

Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis - Drug Profile

**Product Description** 

Mechanism Of Action

Small Molecules for Infected Diabetic Foot Ulcers - Drug Profile

**Product Description** 

Mechanism Of Action

SR-0379 - Drug Profile

**Product Description** 

Mechanism Of Action

Stem Cell Therapy for Diabetic Foot Ulcers - Drug Profile

**Product Description** 

Mechanism Of Action

Stem Cell Therapy for Diabetic Foot Ulcers, Injuries and Liver Diseases - Drug Profile

**Product Description** 



Stempeucel - Drug Profile

**Product Description** 

Mechanism Of Action

suramin - Drug Profile

**Product Description** 

Mechanism Of Action

SymHeal - Drug Profile

**Product Description** 

Mechanism Of Action

tobramycin + triclosan - Drug Profile

**Product Description** 

Mechanism Of Action

TOPN-53 - Drug Profile

**Product Description** 

Mechanism Of Action

TP-102 - Drug Profile

**Product Description** 

Mechanism Of Action

TTAX-01 - Drug Profile

**Product Description** 

Mechanism Of Action

TWB-103 - Drug Profile

**Product Description** 

Mechanism Of Action

udonitrectag - Drug Profile

**Product Description** 

Mechanism Of Action

WF-10 - Drug Profile

**Product Description** 

Mechanism Of Action

Diabetic Foot Ulcers - Dormant Projects

Diabetic Foot Ulcers - Discontinued Products

Diabetic Foot Ulcers - Product Development Milestones

Featured News & Press Releases

Sep 27, 2022: Recce Pharmaceuticals announces expansion and acceleration of clinical programs

Sep 26, 2022: CellResearch to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world's premier diabetic foot conference (DFCon) in Los Angeles



Sep 19, 2022: Ceria Therapeutics awarded a \$300,000 SBIR Grant to advance development of a novel treatment of non-healing diabetic foot ulcers

Sep 16, 2022: CellResearch (CRC) announces positive results of phase I study for CorLiCyte

Aug 10, 2022: Promore Pharma granted EU patent regarding treatment of chronic wounds

Jul 07, 2022: Destiny Pharma announces publication of XF-73 drug synergy data

Apr 21, 2022: Cynata advances clinical trial in Diabetic Foot Ulcers

Apr 12, 2022: MediWound's EscharEx highlighted in poster and oral presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022

Apr 05, 2022: Lakewood-Amedex enrolls first patient in phase 2 clinical trial for patients with chronic diabetic foot Ulcers (cDFU

Mar 29, 2022: MediWound to present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022

Dec 22, 2021: Cynata commences DFU clinical trial

Nov 04, 2021: TechnoPhage announces first clinical safety results with innovative biological product TP-102

Oct 22, 2021: Helixmith announces phase 3 study results of novel gene therapy treatment for diabetic foot ulcers at 2021 Annual Meeting of Diabetic Foot Ulcer Conference (DFCon)

Aug 24, 2021: Another take on TP-102 Phase I/IIa Clinical Trial by Jornal Expresso Jul 09, 2021: MediWound announces peer-reviewed paper detailing Escharex phase 2 randomized control trial results published in the online Wound Repair and Regeneration Journal

Appendix

Methodology

Coverage

Secondary Research

**Primary Research** 

**Expert Panel Validation** 

Contact Us

Disclaimer



# **List Of Tables**

#### LIST OF TABLES

Number of Products under Development for Diabetic Foot Ulcers, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Diabetic Foot Ulcers - Dormant Projects, 2022

Diabetic Foot Ulcers - Discontinued Products, 2022



# **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development for Diabetic Foot Ulcers, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



### I would like to order

Product name: Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type

and Key Players, 2022 Update

Product link: <a href="https://marketpublishers.com/r/D18A140EE977EN.html">https://marketpublishers.com/r/D18A140EE977EN.html</a>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/D18A140EE977EN.html">https://marketpublishers.com/r/D18A140EE977EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



